Article in Cancer discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
19 authors.
Zhihang Chen *Department of Liver Surgery, Center of Hepato-pancreato-biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.ORCID 0000-0003-3927-7069
Xiaoxue Ren *Department of Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.ORCID 0000-0001-5869-1797
Yifan Zhang *Department of Liver Surgery, Center of Hepato-pancreato-biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.ORCID 0009-0007-7400-8880
Youmei Kang *Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.ORCID 0009-0003-6587-0357
Ye Yang *Department of Gastroenterology and Hepatology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.ORCID 0009-0001-9662-7419
Yihang XuDepartment of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.ORCID 0009-0001-9327-6422
Qian ZhouDepartment of Medical Statistics, Clinical Trials Unit, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.ORCID 0000-0003-3954-5449
Changyi LiaoDepartment of Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.ORCID 0009-0001-7390-4372
Qianwen ZengDepartment of Liver Surgery, Center of Hepato-pancreato-biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.ORCID 0000-0003-3296-2688
Xin LiuDepartment of Liver Surgery, Center of Hepato-pancreato-biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.ORCID 0000-0002-7529-3149
Renxuan LinInstitute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.ORCID 0009-0002-3420-7037
Yu YangInstitute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.ORCID 0009-0000-3314-7955
Feng LuoInstitute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.ORCID 0009-0004-4160-4086
Shunli ShenDepartment of Liver Surgery, Center of Hepato-pancreato-biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.ORCID 0000-0001-7931-9193
Sui PengInstitute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.ORCID 0000-0002-7399-2579
Xiaoxing LiInstitute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.ORCID 0000-0001-8791-7505
Jianting LongDepartment of Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.ORCID 0000-0002-1565-0159
Lixia XuDepartment of Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.ORCID 0000-0002-1818-6267
Ming KuangDepartment of Liver Surgery, Center of Hepato-pancreato-biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.ORCID 0000-0002-7397-5779
Funding
China Postdoctoral Science Foundation () 2025M782335China Postdoctoral Science Foundation () BX20240441Key Research and Development Plan of Guangzhou City 202206080016National Health Commission of the People's Republic of China (NHC) 2023ZD0501605National Natural Science Foundation of China (NSFC) 82130083National Natural Science Foundation of China (NSFC) 82372914National Natural Science Foundation of China (NSFC) 82403411National Natural Science Foundation of China (NSFC) 82403590National Natural Science Foundation of China (NSFC) 82503302Special Project for Research and Development in Key areas of Guangdong Province () 2023B1111020007
6 · The paper itself
Abstract
Neutrophils are major players in innate immunity. However, their landscape and functions in colorectal cancer liver metastasis (CRLM) remain poorly understood. In this study, using single-cell RNA sequencing and spatial-enhanced-resolution-omics sequencing, we provide a comprehensive transcriptional landscape of tumor-associated neutrophils (TAN) in CRLM. Our analysis reveals that a terminally differentiated protumor neutrophil subset (TAN1), characterized by a glycolysis signature and a senescent phenotype, is significantly enriched in liver metastasis and associated with poor prognosis. Mechanistically, TAN1 arises from other TAN subsets through the upregulation of BHLHE40, driven by glucose deprivation in the metastatic microenvironment. Functionally, TAN1 promotes angiogenesis via VEGFA and recruits immunosuppressive macrophages through potential CCL3L1-CCR1 signaling, thereby fostering an angiogenic immunosuppressive niche. As a result, neutrophil-specific knockout of Bhlhe40 in mice significantly promotes antitumor immunity and suppresses tumor growth. Our data uncover the critical role of BHLHE40+ senescent-like neutrophils in shaping the immunosuppressive microenvironment of CRLM. SIGNIFICANCE: This study identifies a protumoral BHLHE40+ senescent-like neutrophil subset in CRLM that orchestrates vascular immunosuppressive niches to drive tumor progression, highlighting a potential target for neutrophil-specific therapeutic intervention. See related commentary by Droin and Garner, p. 1958.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Senescent-Like Neutrophils Shape Angiogenic Immunosuppressive Niches in Colorectal Cancer Liver Metastasis. · full record | OpenQuestion